Who Paid My Doc
Wallace Johnson
Hypertension Specialist Baltimore, MD Medical Doctor
NPI 1043253867 CMS profile 991105
22 S Greene St, Baltimore, MD 21201
General payments
$1,503
Research payments
$536
Ownership & investment interest
$0
Research they led as principal investigator
$41,574
Through program year 2025, Wallace Johnson of Baltimore, MD is reported in the CMS Open Payments database as having received $1,503 across 9 general payments and $536 in research payments paid to them. Separately, studies naming them as principal investigator received $41,574 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $111 | 1 | |
| 2024 | General | $761 | 3 | |
| 2023 | Research | $536 | 5 | |
| 2022 | General | $103 | 1 | |
| 2020 | General | $529 | 4 |
Beside peers
- Wallace Johnson
- Maryland median
- Middle half of Maryland
- National median
In program year 2025, general payments to Wallace Johnson were reported at $111. Among 20,588 Maryland profiles paid that year, the median was $166 and the middle half received between $51 and $580.
Show as a table
| Year | Wallace Johnson | Maryland median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $165 | $50–$633 | $163 |
| 2020 | $529 | $114 | $37–$407 | $114 |
| 2021 | $0 | $130 | $36–$480 | $132 |
| 2022 | $103 | $150 | $45–$529 | $149 |
| 2023 | $0 | $155 | $47–$557 | $160 |
| 2024 | $761 | $169 | $53–$600 | $164 |
| 2025 | $111 | $166 | $51–$580 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 50 drugsPart D claims
2,801
Drug cost
$168,309
Branded share of claims
14.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 56 | $59,464 | |
| Jardiance Empagliflozin | Brand | 18 | $27,711 | |
| Januvia Sitagliptin Phosphate | Brand | 13 | $11,346 | |
| Atorvastatin Calcium | Generic | 323 | $6,543 | |
| Eplerenone | Generic | 49 | $6,116 | |
| Ezetimibe | Generic | 82 | $5,545 | |
| Nifedipine Er Nifedipine | Brand | 151 | $5,418 | |
| Clonidine | Generic | 50 | $4,342 | |
| Amlodipine Besylate | Generic | 329 | $4,201 | |
| Losartan Potassium | Generic | 237 | $3,751 |
The 10 drugs with the highest cost, of 50 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 14 billing codesPaid by Medicare
$64,027
Medicare patients
262
Services billed
692
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 49% | |
| Diabetes | 46% | |
| Chronic kidney disease | 40% | |
| Ischemic heart disease | 31% | |
| Heart failure | 23% | |
| Cancer | 23% | |
| Atrial fibrillation | 18% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Vaccine for influenza for injection into muscle 90662 | Office | 26 | 27 | $2,101 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
14 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Hypertension Specialist in Maryland
Practitioners in the same specialty and state, ranked by reported value.
All Hypertension Specialist
Everyone recorded under this specialty, nationwide.
Doctors in Maryland
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.